For Healthcare Professionals Outside the US
Tafinlar + Mekinist is indicated for adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection; for first-line treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation; for adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.

It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Home > Dosing > Managing pyrexia

Manage pyrexia with a simple and established protocol1,2

Three easy steps3*

3 easy steps to help manage pyrexia
3 easy steps to help manage pyrexia
border line

97% of patients experienced resolution of pyrexia after the first dose reduction.4

border line

For Stage III patients with BRAF V600+ melanoma following complete resection5,6

  • Pyrexia was the most common adverse reaction with TAFINLAR + MEKINIST (63% overall, 5% Grade 3) 
  • TAFINLAR + MEKINIST discontinuation rate due to pyrexia was 9% 
     

For patients with BRAF V600+ unresectable or metastatic melanoma3,4:

  • Pyrexia was the most common adverse reaction with TAFINLAR + MEKINIST (58% overall, 6% Grade 3)
  • TAFINLAR + MEKINIST discontinuation rate due to pyrexia was 4%

For patients with BRAF V600+ NSCLC4:

  • Pyrexia was one of the most common adverse reactions, reported by 55% of patients receiving TAFINLAR + MEKINIST
  • 2 patients discontinued TAFINLAR + MEKINIST due to pyrexia
QOL, quality of life.
*See SmPC for additional details.
Or if pyrexia was accompanied by other severe symptoms, including dehydration, hypotension,  or renal failure.
References: 1. Tafinlar Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2020. 2. Mekinist Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2020. 3. Long GV, Stroyakovskiy D, Levchenko E, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877-1888. 4. Tafinlar [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2020. 5. Data on file. Tafinlar + Mekinist Clinical Study Report. Novartis Pharmaceutical Corp; 2018. 6. Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813-1823.   

COVID-19 Update


Novartis is closely monitoring the evolving COVID-19 pandemic. For the most recent information on how Novartis is responding, visit the COVID-19 Information Center.

During this time of uncertainty it is important to communicate with your patients about COVID-19 to clarify that they should not stop their treatments except under the direction of the treating physician, and to ensure that patients have sufficient drug to avoid any treatment interruptions.

Reach out to your Novartis representative with any questions related to Novartis products.

04/20  G-ONC-1230566

COMBI-AD was a double-blind, placebo-controlled, Phase 3 trial that compared Tafinlar + Mekinist vs placebo4

ELIGIBILITY REQUIREMENTS

  • Resection of histologically confirmed Stage IIIA, B, or C with BRAF V600E or BRAF V600K mutation
  • ECOG performance status ≤1
  • No prior systemic anticancer treatment or radiotherapy for melanoma
TAFINLAR 150 mg BID + MEKINIST
2 mg QD (n=438)
imgh22

Placebo (n=432)

STUDY ENDPOINTS

  • Primary endpoint was RFS
  • Secondary endpoints were OS, distant metastasis-free survival, freedom from relapse, and safety
COMBI-d phase 3 study: Tafinlar® (dabrafenib) + Mekinist® (trametinib) vs Tafinlar® monotherapy